Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer according to study
A multi-center study led by researchers at The University of Texas MD Anderson Cancer Center revealed that a liquid biopsy test called Guardant360®, is comparable to standard tissue biopsies in detection of guideline recommended biomarkers in advanced non-small cell lung cancer (NSCLC), has a faster turn-around time, and has the potential to support identification of more patients who can be treated with targeted therapy...
Study finds melanoma brain metastases are immunosuppressive with treatment-resistant metabolism
Melanoma tumors that have spread to the brain are equipped to thwart immunotherapies and targeted therapies that succeed against tumors growing...
New therapeutic target found for aggressive pediatric cancers with few treatment options
Researchers at The University of Texas MD Anderson Cancer Center have discovered that malignant rhabdoid tumors (MRT), a rare pediatric cancer...
MD Anderson supports World Cancer Day call for action to end cancer
As an institution devoted to eliminating cancer for patients in Texas, the nation and around the world, The University of Texas MD Anderson Cancer Center is proud to uphold the mission of World Cancer Day, Feb.4, to unite the global population toward the goal of eradicating the disease.
Established in 2000, the Union for International Cancer Control leads the global World Cancer Day campaign, which aims to save lives by increasing...
